Deals

Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US

Overview

Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US

Significance

Pharmacies with a direct-to-patient (DTP) design present a significant opportunity for clinical trial-related service providers to expand patient access, broaden participant pools, and enhance the patient experience, a strategy highly valued by research and development executives. This approach streamlines access to trial medications and necessary equipment, facilitating smoother clinical trial processes. 

SaveWay Compounding Pharmacy (“SaveWay”) distinguishes itself with a unique business model tailored to customizing medications to meet individual patient needs. With national capabilities, SaveWay is able to dispense medications directly to patients across the United States. SaveWay's pharmacy services and capabilities made them the ideal transaction partner for Myonex to effectively address patient needs for both Investigational Medicinal Products (IMP) and commercial drug access. This partnership will also enhance Myonex’s ability to implement Decentralized Clinical Trials (DCT) and hybrid studies with the ability to deliver unblinded comparator drugs via its CTRX card, and blinded comparator drug shipped directly to patients. 

Crosstree’s Role

Crosstree’s granular Pharma Services expertise helped Myonex identify SaveWay as the ideal partner to increase their clinical trial services nationwide by: 

  • Helping Myonex identify SaveWay as the right partner to accelerate their growth, maximize synergies and optimize cultural fit 
  • Leveraging market expertise to identify the ideal partner
  • Managing the due diligence process timeline to bring the transaction to a successful outcome

Sub-Sector

Pharma Services

Type

Merger and Acquisition

Deal Tags

Clinical Trials
Decentralized Trials
Pharma Development
Healthcare
Pharma Supply Chain